You are here

Low dose paroxetine for menopausal hot flushes


Against the advice of its Reproductive Health Drugs Advisory Committee, the US Federal Drugs Administration (FDA) has licenced the long established SSRI antidepressant paroxitene, in a 7.5mg formulation, for the treatment of menopausal hot flushes. The new low dose tablets will be marketed in the US under the name Brisdelle.   Presumably the FDA was influenced by two new randomised trials showing efficacy, but their advisory committee were worried about side effects. Some commentators have wondered if the new formulation/indication is a thinly veiled way to extend patent protection for this popular antidepressant.

Read the full story here


Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.



Commentaries by Editor Prof. Jim Thornton